Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC”) device ...
Boston Scientific stock (NYSE: BSX) has gained 3% in the five days since its Q4 earnings report last week. Although the company exceeded expectations with both its results and guidance, the modest ...
Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The equity market continued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback